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chronic GVHD was 4%. 5 children died due to transplant
related mortality (TRM), all of them were class 3 Thalas-
semia; 2 patients transplanted from unrelated donor and
unrelated cord and 2 died after second HSCT. Causes of
deaths were severe infections secondary to engraftment
failure; severe hemorrhagic cystitis and multiorgan failure;
pulmonary and intracranial bleeding during engraftment
and TTP. 1 child died 3.5 years after HSCT from severe
multisystemic GVHD and complications of immunosup-
pressive therapy.
Conclusion: Our results showed that children with hemo-
globinopathy who received HSCT had excellent results with
survival above 80% despite of majority of patients with
class 3 Thalassemia and number of children who under-
went second HSCT. Factors affecting prognosis were:
advanced class of Thalassemia type of donor and second
HSCT with myeloablative regimen. Engraftment failure
continues to be a problem for Thalassemia patients. There
is a need for controlled trials to evaluate the effectiveness
of different treatment regimens for speciﬁc group of
patients.325
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Background: Hematopoietic stem cell transplant is a
curative option for a variety of non-malignant, sub-lethal
genetic diseases in children. However, the probability of
ﬁnding a suitable histocompatible sibling donor is less than
30%, especially for patients with genetic diseases, whose
siblings may also carry the affected gene. The use of
matched unrelated donors (MUD) for patients with genetic
diseases is limited by regimen related toxicity (RRT), highrates of graft failure/rejection and graft-versus-host-disease
(GVHD).
Objective: To determine if the reduced toxicity conditioning
regimen: Alemtuzmab with Busulfan, Fludarabine and
reduced dose of cyclophosphamide, would maintain
adequate immune-suppression and allow for acceptable rates
of sustained donor engraftment, low rates of RRT and GVHD.
Methods: 15 eligible patients were consented at Children’s
Hospital Los Angeles between 2007 and 2013. The condi-
tioning regimen consisted of Busulfan 16mg/kg, Alemtuzmab
52mg/m2, Fludarabine 140mg/m2and Cyclophosphamide
105mg/kg. GVHD prophylaxis consisted of Tacrolimus and
Methylprednisolone.
Results: The study population was 73.3% male with me-
dian age 7 (0.8e17.6) years old at transplant. Patients
diagnoses included HLH (n¼2), CD-40 ligand deﬁciency
(n¼2), congenital dyserythropoietic anemia (n¼2), adre-
noleukodystrophy (n¼1), Sickle Cell Disease (n¼7), Thal-
assemia (n¼1). The mean total nucleated cell count (TNC)
and CD34 dose was 5.6x108 ( 2.2x108) cells/kg and
6.4x106 ( 3.4x106) cells/kg respectively. The mean
Busulfan CSS and AUC were 888 ( 242) mg/L and 1297
( 363) mmol/L-min, respectively. The median time to
clearance of Alemtuzmab was 14 (4 to 21) days. Median
time to neutrophil engraftment and platelet engraftment
were 15 (12e28) and 25 (17e30) days respectively. One
patient had primary graft loss. Two patients had second-
ary graft loss. For 11 patients who reached and sustained
engraftment, 9 patient’s donor chimerism were more than
97% and 2 patient’s donor chimerism was 78.1% and 82%
respectively, in the most recent follow up. There were no
cases of Grade III/IV, mucositis or acute GVHD (aGVHD).
Two patients developed mild sinusoidal obstruction
syndrome (SOS). Nine patients had detectable viral reac-
tivation. Only 1 patient developed extensive cGVHD. One
patient expired due to progressive encephalopathy and
multi-organ failure. The median length of follow-up was 2
(0.2-5.4) years. The overall survival (OS) and disease free
survival (DFS) at 5 years were 93.3% and 73.3%
respectively.
Conclusion: This Alemtuzmab-based reduced toxicity
regimen appears promising with durable unrelated donor
engraftment, effective cure of clinical disease, and low rates
of RRT and GVHD. The major adverse effect was activation of
viral infections.
